Stockscreener 앱 받기
1.41
0.70%
-0.01
전일 마감가:
$1.42
열려 있는:
$1.42
하루 거래량:
100.66K
Relative Volume:
0.37
시가총액:
$14.12M
수익:
$996.00K
순이익/손실:
$-6.09M
주가수익비율:
-2.6604
EPS:
-0.53
순현금흐름:
$-9.76M
1주 성능:
+15.57%
1개월 성능:
+59.47%
6개월 성능:
-8.44%
1년 성능:
-25.00%
1일 변동 폭
$1.32
$1.54
1주일 범위
$1.16
$1.54
52주 변동 폭
$0.70
$2.44
Therapeuticsmd Inc Stock (TXMD) Company Profile
명칭
Therapeuticsmd Inc
전화
561-961-1900
주소
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
TXMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
1.41 | 14.12M | 996.00K | -6.09M | -9.76M | -0.53 |
|
ZTS
Zoetis Inc
|
157.37 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.36 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.59 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.42 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
296.07 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-08-07 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2020-05-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-12-02 | 개시 | Guggenheim | Buy |
| 2019-10-17 | 개시 | H.C. Wainwright | Buy |
| 2019-04-30 | 재개 | Noble Capital Markets | Outperform |
| 2018-06-15 | 개시 | JP Morgan | Overweight |
| 2017-09-08 | 개시 | Morgan Stanley | Equal-Weight |
| 2017-07-11 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2017-05-09 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2016-11-22 | 재개 | Jefferies | Buy |
| 2016-11-22 | 개시 | Oppenheimer | Outperform |
| 2016-11-07 | 재개 | Guggenheim | Buy |
| 2016-04-04 | 개시 | Goldman | Buy |
| 2015-12-08 | 재확인 | Jefferies | Buy |
| 2015-12-08 | 재확인 | Stifel | Buy |
| 2015-09-21 | 재확인 | Jefferies | Buy |
| 2015-06-09 | 개시 | Guggenheim | Buy |
| 2014-07-08 | 개시 | FBR Capital | Outperform |
| 2014-04-17 | 재확인 | Noble Financial | Buy |
| 2014-01-28 | 재확인 | Noble Financial | Buy |
모두보기
Therapeuticsmd Inc 주식(TXMD)의 최신 뉴스
StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
Press Release Distribution & PR Platform - ACCESS Newswire
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com - Defense World
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com - Defense World
TherapeuticsMD CEO Marlan Walker acquires $489 in common stock By Investing.com - Investing.com Canada
TherapeuticsMD director Tommy Thompson acquires $325 in stock - Investing.com Australia
TherapeuticsMD director Tommy Thompson acquires $325 in stock By Investing.com - Investing.com Canada
TherapeuticsMD CEO Marlan Walker acquires $489 in common stock - Investing.com
TherapeuticsMD CEO Marlan Walker buys $489 in common stock By Investing.com - Investing.com South Africa
TherapeuticsMD CEO Marlan Walker buys $489 in common stock - Investing.com
INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm - ACCESS Newswire
DEADLINE TODAY: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm - ACCESS Newswire
Mayne Pharma Faces Legal Challenge from TherapeuticsMD - TipRanks
TherapeuticsMD CEO Marlan Walker buys $1,994 in stock - Investing.com Australia
TherapeuticsMD CEO Marlan Walker buys $1,994 in stock By Investing.com - Investing.com India
TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch
TherapeuticsmdFiles Lawsuit Against Mayne Pharma For Breach Of Contract - marketscreener.com
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com - Defense World
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Full Year 2024 Earnings: US$0.20 loss per share (vs US$0.74 loss in FY 2023) - Yahoo Finance
TherapeuticsMD Reports Improved Financial Performance - TipRanks
DEADLINE MONDAY: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017 -- TXMD - ACCESS Newswire
TherapeuticsMD Inc. (TXMD) reports earnings - Quartz
TherapeuticsMD Reports Reduced Losses and Revenue Growth - TipRanks
TherapeuticsMD Announces Full Year 2024 Financial Results - Business Wire
Therapeuticsmd Inc (TXMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Therapeuticsmd Inc 주식 (TXMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Walker Marlan D | Chief Executive Officer |
Apr 14 '25 |
Buy |
1.00 |
490 |
489 |
73,639 |
| Walker Marlan D | Chief Executive Officer |
Apr 10 '25 |
Buy |
0.86 |
1,167 |
1,000 |
73,149 |
| Walker Marlan D | Chief Executive Officer |
Apr 09 '25 |
Buy |
0.87 |
1,136 |
994 |
71,982 |
| Collins Cooper C. | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
60,516 |
| Naughton Gail K | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
8,500 |
| Thompson Tommy G | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
14,454 |
| Walker Marlan D | Chief Executive Officer |
Feb 18 '25 |
Option Exercise |
0.00 |
8,281 |
0 |
70,846 |
| Collins Cooper C. | Director |
Aug 22 '24 |
Buy |
1.73 |
4,094 |
7,099 |
52,016 |
| Collins Cooper C. | Director |
Aug 21 '24 |
Buy |
1.70 |
1,200 |
2,039 |
47,922 |
1.38%
0.87%
자본화:
|
볼륨(24시간):